Of the 84 patients, 36 (42.9%) developed HT during the 1-year follow-up, and prevalence of HT was significantly higher among those with elevated hs-cTnT levels within 48 h after admission (55.1 vs25.7%, P = 0.007) (Table 3).After adjusting for age, sex, hypertension, renal impairment and NIHSS score on admission, risk of HT in patients with elevated hs-cTnT levels was 4.0-fold higher (95%CI 1.391 to 11.625,P = 0.01) than in patients with normal hs-cTnT levels (Table 4). The gene discussed is TNNT2; the disease is hematocrit.